Global Tumor NGS Genetic Testing Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Tumor NGS Genetic Testing Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Tumor NGS Genetic Testing is to use high-throughput sequencing to understand tumors at the genetic level, detect and quantify the genetic components that drive tumors.
Tumor NGS Genetic Testing report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Tumor NGS Genetic Testing market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Companion Diagnostics and Early Cancer Screening are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Tumor NGS Genetic Testing industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Tumor NGS Genetic Testing key companies include Foundation Medicine, Guardant Health, Illumina, Thermo Fisher Scientific Inc., DIAN DIAGNOSTICS Group Co., Ltd., Burning Rock Biotech., NovogeneCo.,Ltd., Nanjing Shihejiyin Technology, Inc. and Amoy Diagnostics Co.,Ltd., etc. Foundation Medicine, Guardant Health, Illumina are top 3 players and held % share in total in 2022.
Tumor NGS Genetic Testing can be divided into Liquid Biopsy (Blood Sample) and Tissue Biopsy, etc. Liquid Biopsy (Blood Sample) is the mainstream product in the market, accounting for % share globally in 2022.
Tumor NGS Genetic Testing is widely used in various fields, such as Companion Diagnostics, Early Cancer Screening and Drug Discovery,, etc. Companion Diagnostics provides greatest supports to the Tumor NGS Genetic Testing industry development. In 2022, global % share of Tumor NGS Genetic Testing went into Companion Diagnostics filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Tumor NGS Genetic Testing market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Foundation Medicine
Guardant Health
Illumina
Thermo Fisher Scientific Inc.
DIAN DIAGNOSTICS Group Co., Ltd.
Burning Rock Biotech.
NovogeneCo.,Ltd.
Nanjing Shihejiyin Technology, Inc.
Amoy Diagnostics Co.,Ltd.
China National Pharmaceutical Group Corporation
Shanghai Fosun Pharmaceutical(Group)Co.,Ltd.
Guangzhou Kingmed Diagnostics Group Co.,Ltd.
ADICON Clinical Laboratories, Inc.
Genetron
Genecast Group Inc.
BGI Genomics Co.,Ltd.
Beijing-Geneplus Technology Limited.
Xiamen SpacegenCo., Ltd.
Geneis（Beijing）Co.Ltd.
HaploX
Segment by Type
Liquid Biopsy (Blood Sample)
Tissue Biopsy
Companion Diagnostics
Early Cancer Screening
Drug Discovery
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Tumor NGS Genetic Testing market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Tumor NGS Genetic Testing introduction, etc. Tumor NGS Genetic Testing Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Tumor NGS Genetic Testing market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Tumor NGS Genetic Testing report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Tumor NGS Genetic Testing market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Companion Diagnostics and Early Cancer Screening are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Tumor NGS Genetic Testing industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Tumor NGS Genetic Testing key companies include Foundation Medicine, Guardant Health, Illumina, Thermo Fisher Scientific Inc., DIAN DIAGNOSTICS Group Co., Ltd., Burning Rock Biotech., NovogeneCo.,Ltd., Nanjing Shihejiyin Technology, Inc. and Amoy Diagnostics Co.,Ltd., etc. Foundation Medicine, Guardant Health, Illumina are top 3 players and held % share in total in 2022.
Tumor NGS Genetic Testing can be divided into Liquid Biopsy (Blood Sample) and Tissue Biopsy, etc. Liquid Biopsy (Blood Sample) is the mainstream product in the market, accounting for % share globally in 2022.
Tumor NGS Genetic Testing is widely used in various fields, such as Companion Diagnostics, Early Cancer Screening and Drug Discovery,, etc. Companion Diagnostics provides greatest supports to the Tumor NGS Genetic Testing industry development. In 2022, global % share of Tumor NGS Genetic Testing went into Companion Diagnostics filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Tumor NGS Genetic Testing market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Foundation Medicine
Guardant Health
Illumina
Thermo Fisher Scientific Inc.
DIAN DIAGNOSTICS Group Co., Ltd.
Burning Rock Biotech.
NovogeneCo.,Ltd.
Nanjing Shihejiyin Technology, Inc.
Amoy Diagnostics Co.,Ltd.
China National Pharmaceutical Group Corporation
Shanghai Fosun Pharmaceutical(Group)Co.,Ltd.
Guangzhou Kingmed Diagnostics Group Co.,Ltd.
ADICON Clinical Laboratories, Inc.
Genetron
Genecast Group Inc.
BGI Genomics Co.,Ltd.
Beijing-Geneplus Technology Limited.
Xiamen SpacegenCo., Ltd.
Geneis（Beijing）Co.Ltd.
HaploX
Segment by Type
Liquid Biopsy (Blood Sample)
Tissue Biopsy
Segment by Application
Companion Diagnostics
Early Cancer Screening
Drug Discovery
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Tumor NGS Genetic Testing market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Tumor NGS Genetic Testing introduction, etc. Tumor NGS Genetic Testing Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Tumor NGS Genetic Testing market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices